┌──────────────────────────────────────────────────────────────┐ RECORD TYPE ......... SUBJECT FILE SUBJECT TYPE ........ ORG FILE OPENED ......... 2026-07-05 17:23 UTC APPEARANCES ......... 3 ANNOTATIONS KNOWN ALIASES ....... 3 └──────────────────────────────────────────────────────────────┘
Restoring Invisible and Abandoned Trials (RIAT) initiative
ALSO APPEARS AS
- RIAT
- Restoring Invisible and Abandoned Trials (RIAT) Initiative
- Restoring Invisible and Abandoned Trials (RIAT) initiative
APPEARS IN THE MARGINS OF
- Study 329 Adverse Event Data Exclusion and FDA Disclosure
Study 329, a clinical trial of paroxetine (Paxil) in adolescents with major depressive disorder, was conducted from 1994 to 1998 and initially published in 2001 by Keller and colleagues. This original…
- FDA Internal Review of Study 329 Adverse Events Pre-RIAT
Study 329 was a clinical trial conducted by SmithKline Beecham (now GlaxoSmithKline) between 1994 and 1998, investigating the efficacy and safety of paroxetine and imipramine in adolescents with major…
- Study 329: Contents of Appendix H and GSK's Data Provision to RIAT
Study 329 was a clinical trial sponsored by SmithKline Beecham (now GSK) investigating paroxetine in adolescents with depression. The original published results by Keller et al. in 2001 were subsequen…